Zymeworks Inc. (ZYME) director equity grants disclosed on Form 4 filing

Rhea-AI Filing Summary

Zymeworks Inc. reported that director Robert E. Landry received new equity awards. On January 12, 2026, he was granted stock options to buy 11,500 shares of common stock at an exercise price of $23.16 per share. These options vest on January 12, 2027 and expire on January 11, 2036, leaving him with 11,500 derivative securities beneficially owned after the grant.

On the same date, he was also granted 7,700 restricted stock units (RSUs), each representing the contingent right to receive one share of common stock upon vesting. These RSUs vest on January 12, 2027, and 7,700 derivative securities are shown as beneficially owned directly following the transactions.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Landry Robert E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	11,500	$0.00	--
Grant/Award	Restricted Stock Unit	7,700	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 11,500 shares (Direct); Restricted Stock Unit — 7,700 shares (Direct)

Footnotes (1)

1. Stock options vest on January 12, 2027. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. RSUs vest on January 12, 2027.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Landry Robert E

(Last) (First) (Middle)

C/O ZYMEWORKS INC.

108 PATRIOT DRIVE, SUITE A

(Street)

MIDDLETOWN DE 19709

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zymeworks Inc. [ ZYME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.16	01/12/2026		A		11,500		01/12/2027(1)	01/11/2036	Common Stock	11,500	$0.00	11,500	D
Restricted Stock Unit	(2)	01/12/2026		A		7,700		01/12/2027(3)	01/12/2027(3)	Common Stock	7,700	$0.00	7,700	D

Explanation of Responses:

1. Stock options vest on January 12, 2027.

2. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.

3. RSUs vest on January 12, 2027.

	/s/ Daniel Dex, Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ZYME director Robert E. Landry report?

Director Robert E. Landry reported grants of 11,500 stock options and 7,700 restricted stock units in Zymeworks Inc. on January 12, 2026.

What are the terms of Robert E. Landry’s ZYME stock options?

Landry received stock options for 11,500 shares of Zymeworks common stock with an exercise price of $23.16 per share, vesting on January 12, 2027 and expiring on January 11, 2036.

How many restricted stock units did the ZYME director receive?

Robert E. Landry received 7,700 RSUs, each representing the right to receive one share of Zymeworks common stock upon vesting.

When do Robert E. Landry’s Zymeworks RSUs vest?

The RSUs granted to Robert E. Landry vest on January 12, 2027, as disclosed in the filing footnotes.

Are the reported ZYME option and RSU holdings direct or indirect?

Both the 11,500 stock options and 7,700 RSUs are reported as held with direct beneficial ownership.

What does each ZYME restricted stock unit represent for the director?

Each Zymeworks RSU represents the contingent right to receive, upon vesting, one share of the company’s common stock.